Abstract
Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
